COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer.

Details

Language :

English

ISSN :

0732183X

Volume :

40

Issue :

29

Database :

Supplemental Index

Journal :

Journal of Clinical Oncology

Publication Type :

Academic Journal

Accession number :

159502167

Full Text :

https://doi.org/10.1200/JCO.22.00227